• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Galcanezumab reduces the frequency of episodic cluster headaches

byDayton McMillan
July 23, 2019
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with episode cluster headaches randomized to receive galcanezumab experienced a greater decline in frequency of headaches 1 to 3 weeks after treatment compared to placebo treated patients.

2. Injection-site pain occurred in patients receiving galcanezumab, though no notable differences in overall adverse events was seen between treatment and placebo groups.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Episodic cluster headaches are a disabling condition that occurs in bouts separated by headache free periods. Reduced quality of life is associated with the headaches, affecting patient’s daily functioning, work, and mental health. Present treatment is aimed at reducing frequency of the attacks, though no medication is specifically approved for prevention the condition. The antibody galcanezumab, which binds and inhibits the calcitonin gene-related peptide (CGRP), has been effective for migraine treatment and its use for cluster headaches is of interest. The primary outcome of the study, reduction in headache frequency from weeks 1 to 3 of the study, showed a significantly higher reduction in galcanezumab treated patients compared to those treated with placebo. While those in the treatment group experienced a higher rate of injection site pain, no notable difference in adverse events was observed between the treatment groups.

This study provides supporting evidence for a first-in-class treatment for episodic cluster headaches by showing notable declines in headache frequency in treated patients, though the size of the trial and length of follow-up are both weaknesses that may limit the study’s impact.

Click to read the study in NEJM

RELATED REPORTS

Higher peak expiratory flow associated with decreased headache risk in middle-aged and older adults

Cervical medial branch blocks may offer therapeutic benefit for facet-mediated neck pain

Predictors and outcomes associated with prolonged hospital length of stay in intracerebral hemorrhage

Relevant Reading: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

In-Depth [randomized controlled trial]: This international, blinded, randomized controlled trial enrolled patients from 2015 to 2018. Eligible adult patients had a history of episode cluster headache and could distinguish a cluster headache from other headaches. Patients had to have headaches occurring at least once every other day and no more than 8 attaches per day during a 7-day enrollment period. Patients were allowed to continue use of treatments for active cluster headaches but could be on no type of preventative treatment. Patients were randomized to a galcanezumab (n=49) or placebo (n=57) group and given a subcutaneous injection at baseline and 1-month. Patients self-recorded information about the frequency and quality of their cluster headaches during the trial. The primary end point, mean reduction in cluster headaches through weeks 1 to 3 of the trial, was 8.7 in the treatment group compared to 5.2 in the placebo group (difference in mean change, 3.5 attacks per week; 95% confidence interval [CI], 0.2 to 6.7; P=0.04). In weeks 1 to 3, the mean reduction in weekly headaches was 52% in the treatment group compared to 27% in the placebo group. At week 3, the percent of patients that had at least a 50% reduction in headache frequency was 71% and 53% in the treatment and placebo groups, respectively (P=0.046). Adverse events occurred in 43% vs 33% of the treatment and placebo groups, respectively. Injection-site related pain occurred in 8% of the treatment group and in no placebo patients (P=0.04). No differences were observed in patient laboratory values, vital signs, or electrocardiographic variables.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: calcitonin gene-related peptide (CGRP)Cluster Headachegalcanezumabheadache
Previous Post

2 Minute Medicine Rewind July 22, 2019

Next Post

Quick Take: Association of nonmedical prescription opioid use with subsequent heroin use initiation in adolescents

RelatedReports

Significant number of wrong-patient errors in radiology reports
Neurology

Higher peak expiratory flow associated with decreased headache risk in middle-aged and older adults

August 25, 2025
Parental nonmedical prescription opioid use linked to adolescent use
Chronic Disease

Cervical medial branch blocks may offer therapeutic benefit for facet-mediated neck pain

August 9, 2025
Emergency

Predictors and outcomes associated with prolonged hospital length of stay in intracerebral hemorrhage

July 19, 2025
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Chronic Disease

MLC901 may be effective in treatment of post-concussion symptoms in phase III study

July 17, 2025
Next Post
National acute HCV infections may be underestimated

Quick Take: Association of nonmedical prescription opioid use with subsequent heroin use initiation in adolescents

Systematic review examines benefits and adverse effects of cannabinoid therapy

Quick Take: Association of marijuana laws with teen marijuana use

Large proportion of late preterm infants and older admitted to the NICU

Neonates with isolated historical fever likely at lower risk for serious bacterial infection

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Significant body weight reduction with cagrilintide-semaglutide therapy
  • Machine learning models diagnose celiac disease at similar performance levels to pathologists
  • Presymptomatic treatment of spinal muscular atrophy with risdiplam leads to improved functional outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.